Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts
🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, according to TD Cowen analysts. The Pennsylvania drugmaker ...
May 6, 2026 11:17 AM EDT News Briefing Madrigal MASH drug beats expectations; Gilead cuts jobs; investment firm debuts ENDPOINTS 🚀 Madrigal Pharmaceuticals’ MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that